EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real-world outcomes of everolimus-based therapy after CDK4/6 inhibitor therapy in ER-positive/HER2-negative metastatic breast cancer: a multicenter registry-based study

Hikari Kiyohara, Toru Hanamura, Yasuaki Sagara, Minoru Miyashita, Shigehira Saji, Naoki Niikura

Breast Cancer · 10.11.2026

DOI: 10.1007/s12282-026-01931-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer, online erschienen am 10.11.2026. Verfasst von Hikari Kiyohara und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Oncology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Tokai University, Isehara Campus.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Everolimus-based endocrine therapy is used for estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER-positive/HER2-negative) metastatic breast cancer after cyclin-dependent kinase 4/6 (CDK4/6) inhibitor treatment, but factors associated with treatment durability remain unclear. We evaluated real-world outcomes and associated factors. METHODS: This multicenter retrospective registry study included patients who received everolimus-based endocrine therapy after CDK4/6 inhibitor treatment. The primary endpoint was time to treatment failure (TTF). Overall survival (OS), treatment response, and exploratory post-TTF survival were also evaluated. Associations were analyzed using Firth-penalized Cox and logistic regression models. RESULTS: Among 169 eligible patients, median TTF and OS were 4.1 months (95% confidence interval [CI], 3.2-4.8) and 28.7 months (95% CI, 24.9-39.0), respectively. Non-ductal histology, progesterone receptor (PgR) expression

Schlagwörter

Stichwörter der Autor:innen

CDK4/6 inhibitorEndocrine therapyEverolimusMetastatic breast cancerReal-world evidence

Autor:innen und Institutionen

  • Department of Breast Oncology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.
  • Department of Breast Oncology, Social Medical Corporation Hakuaikai Sagara Hospital, 3-31 Matsubara-Cho, Kagoshima, 892-0833, Japan.
  • Department of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-Machi, Aoba-Ku, Sendai, Miyagi, 980-8575, Japan.
  • Department of Medical Oncology, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
  • Department of Breast Oncology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan. nniikura@tokai.ac.jp.

Förderung

  • Tokai University, Isehara Campus

Zitieren

APA

Kiyohara, H., Hanamura, T., Sagara, Y., Miyashita, M., Saji, S., & Niikura, N. (2026). Real-world outcomes of everolimus-based therapy after CDK4/6 inhibitor therapy in ER-positive/HER2-negative metastatic breast cancer: a multicenter registry-based study. Breast Cancer. https://doi.org/10.1007/s12282-026-01931-7

Vancouver

Kiyohara H, Hanamura T, Sagara Y, Miyashita M, Saji S, Niikura N. Real-world outcomes of everolimus-based therapy after CDK4/6 inhibitor therapy in ER-positive/HER2-negative metastatic breast cancer: a multicenter registry-based study. Breast Cancer. 2026. doi:10.1007/s12282-026-01931-7

BibTeX
@article{Kiyohara2026,
  author = {Kiyohara, Hikari and Hanamura, Toru and Sagara, Yasuaki and Miyashita, Minoru and Saji, Shigehira and Niikura, Naoki},
  title = {Real-world outcomes of everolimus-based therapy after CDK4/6 inhibitor therapy in ER-positive/HER2-negative metastatic breast cancer: a multicenter registry-based study},
  journal = {Breast Cancer},
  year = {2026},
  doi = {10.1007/s12282-026-01931-7}
}
Kostenlos starten →